Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24058035 | 0.84 | DGAT1 (0.51) | LPLLIPGDGAT1EGFRMRGPRX4 | |
| SCHEMBL9985660 | 0.82 | DGAT1 (0.49) | LPLLIPGDGAT1F11EGFR | |
| SCHEMBL27345508 | 0.80 | HIF1A (0.42) | LPLLIPGDGAT1F11EGFR | |
| SCHEMBL21568905 | 0.80 | LPL (0.59) | LPLLIPGDGAT1 | |
| SCHEMBL258005 | 0.80 | DGAT1 (0.64) | LPLLIPGDGAT1F11ESR2 | |
| SCHEMBL14673623 | 0.79 | SMN1; SMN2 (0.46) | LPLLIPGDGAT1F11ALDH1A1 | |
| SCHEMBL4378064 | 0.78 | LPL (0.53) | LPLLIPGDGAT1ALDH1A1 | |
| SCHEMBL21054557 | 0.78 | DGAT1 (0.43) | LPLLIPGDGAT1EGFR | |
| SCHEMBL18874632 | 0.78 | NPC1 (0.45) | LPLLIPGDGAT1F11EGFR | |
| SCHEMBL25244265 | 0.77 | LPL (0.49) | LPLLIPGDGAT1F11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11974999-B2 | Bruton's tyrosine kinase inhibitors | Liao, Xibin (US) | 2024-05-07 | — | — | US | disclosed |
| US-11554118-B2 | Bruton's tyrosine kinase inhibitors | Liao, Xibin (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210121458-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Suzhou Baijibugong Pharmaceutical Technology Co., Ltd. (CN) | 2021-04-29 | — | — | US | disclosed |
| US-20210121458-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Suzhou Baijibugong Pharmaceutical Technology Co., Ltd. (CN) | 2021-04-29 | — | — | US | disclosed |
| US-20210107903-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Suzhou Baijibugong Pharmaceutical Technology Co., Ltd. (CN) | 2021-04-15 | — | — | US | disclosed |
| US-20210107903-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Suzhou Baijibugong Pharmaceutical Technology Co., Ltd. (CN) | 2021-04-15 | — | — | US | disclosed |
| US-10933063-B2 | Bruton's tyrosine kinase inhibitors | Liao, Xibin (US) | 2021-03-02 | — | — | US | disclosed |
| US-10933063-B2 | Bruton's tyrosine kinase inhibitors | Liao, Xibin (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3601264-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Liao, Xibin (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190275037-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | LIAO, XIBIN | 2019-09-12 | — | — | US | disclosed |
| US-20190275037-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | LIAO, XIBIN | 2019-09-12 | — | — | US | disclosed |
| WO-2018175512-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUZHOU BAIJIBUGONG PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11974999-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | LPL 4033/4885LIPG 2961/4885DGAT1 3427/4885 |
| US-20210107903-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | LPL 4033/4885LIPG 2961/4885DGAT1 3427/4885 |
| US-10933063-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | LPL 4033/4885LIPG 2961/4885DGAT1 3427/4885 |
| US-20190275037-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | LPL 4033/4885LIPG 2961/4885DGAT1 3427/4885 |
| US-20210121458-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | LPL 4033/4885LIPG 2961/4885DGAT1 3427/4885 |
| US-11554118-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | LPL 4033/4885LIPG 2961/4885DGAT1 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.